Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 144

1.

A clinically relevant gene signature in triple negative and basal-like breast cancer.

Rody A, Karn T, Liedtke C, Pusztai L, Ruckhaeberle E, Hanker L, Gaetje R, Solbach C, Ahr A, Metzler D, Schmidt M, Müller V, Holtrich U, Kaufmann M.

Breast Cancer Res. 2011 Oct 6;13(5):R97. doi: 10.1186/bcr3035.

2.

Prognostic evaluation of the B cell/IL-8 metagene in different intrinsic breast cancer subtypes.

Hanker LC, Rody A, Holtrich U, Pusztai L, Ruckhaeberle E, Liedtke C, Ahr A, Heinrich TM, Sänger N, Becker S, Karn T.

Breast Cancer Res Treat. 2013 Jan;137(2):407-16. doi: 10.1007/s10549-012-2356-2. Epub 2012 Dec 16.

PMID:
23242614
3.

Homogeneous datasets of triple negative breast cancers enable the identification of novel prognostic and predictive signatures.

Karn T, Pusztai L, Holtrich U, Iwamoto T, Shiang CY, Schmidt M, Müller V, Solbach C, Gaetje R, Hanker L, Ahr A, Liedtke C, Ruckhäberle E, Kaufmann M, Rody A.

PLoS One. 2011;6(12):e28403. doi: 10.1371/journal.pone.0028403. Epub 2011 Dec 29.

4.

Melanoma antigen family A identified by the bimodality index defines a subset of triple negative breast cancers as candidates for immune response augmentation.

Karn T, Pusztai L, Ruckhäberle E, Liedtke C, Müller V, Schmidt M, Metzler D, Wang J, Coombes KR, Gätje R, Hanker L, Solbach C, Ahr A, Holtrich U, Rody A, Kaufmann M.

Eur J Cancer. 2012 Jan;48(1):12-23. doi: 10.1016/j.ejca.2011.06.025. Epub 2011 Jul 7.

PMID:
21741824
5.

Differences in autophagy-related activity by molecular subtype in triple-negative breast cancer.

Kim S, Jung WH, Koo JS.

Tumour Biol. 2012 Oct;33(5):1681-94. doi: 10.1007/s13277-012-0424-1. Epub 2012 May 27.

PMID:
22638807
6.

Molecular anatomy of breast cancer stroma and its prognostic value in estrogen receptor-positive and -negative cancers.

Bianchini G, Qi Y, Alvarez RH, Iwamoto T, Coutant C, Ibrahim NK, Valero V, Cristofanilli M, Green MC, Radvanyi L, Hatzis C, Hortobagyi GN, Andre F, Gianni L, Symmans WF, Pusztai L.

J Clin Oncol. 2010 Oct 1;28(28):4316-23. doi: 10.1200/JCO.2009.27.2419. Epub 2010 Aug 30. Erratum in: J Clin Oncol. 2010 Nov 10;28(32):4868. J Clin Oncol. 2012 Feb 20;30(6):679.

7.

Triple negative breast cancer in Korea-distinct biology with different impact of prognostic factors on survival.

Lee JA, Kim KI, Bae JW, Jung YH, An H, Lee ES; Korean Breast Cancer Society.

Breast Cancer Res Treat. 2010 Aug;123(1):177-87. doi: 10.1007/s10549-010-0998-5. Epub 2010 Jun 24.

PMID:
20574671
8.

[Triple-negative breast cancer: analysis of patients diagnosed and/or treated at the Masaryk Memorial Cancer Institute between 2004 and 2009].

Svoboda M, Navrátil J, Fabian P, Palácová M, Gombošová J, Slámová L, Princ D, Syptáková B, Kudláček A, Bílek O, Pospíšil P, Kazda T, Grell P, Poprach A, Selingerová I, Nenutil R, Juráček J, Héžová R, Slabý O, Vyzula R.

Klin Onkol. 2012;25(3):188-98. Czech. Erratum in: Klin Onkol. 2013;26(2):139.

PMID:
22724568
9.

Vimentin as a poor prognostic factor for triple-negative breast cancer.

Yamashita N, Tokunaga E, Kitao H, Hisamatsu Y, Taketani K, Akiyoshi S, Okada S, Aishima S, Morita M, Maehara Y.

J Cancer Res Clin Oncol. 2013 May;139(5):739-46. doi: 10.1007/s00432-013-1376-6. Epub 2013 Jan 26.

PMID:
23354842
10.

Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancer.

Ono M, Tsuda H, Shimizu C, Yamamoto S, Shibata T, Yamamoto H, Hirata T, Yonemori K, Ando M, Tamura K, Katsumata N, Kinoshita T, Takiguchi Y, Tanzawa H, Fujiwara Y.

Breast Cancer Res Treat. 2012 Apr;132(3):793-805. doi: 10.1007/s10549-011-1554-7. Epub 2011 May 12.

PMID:
21562709
11.
12.

Prognostic impact of the cancer stem cell related markers ALDH1 and EZH2 in triple negative and basal-like breast cancers.

De Brot M, Rocha RM, Soares FA, Gobbi H.

Pathology. 2012 Jun;44(4):303-12. doi: 10.1097/PAT.0b013e3283534bcb.

PMID:
22544210
13.
14.

CD8+ lymphocyte infiltration is an independent favorable prognostic indicator in basal-like breast cancer.

Liu S, Lachapelle J, Leung S, Gao D, Foulkes WD, Nielsen TO.

Breast Cancer Res. 2012 Mar 15;14(2):R48.

15.

MiR-34b is associated with clinical outcome in triple-negative breast cancer patients.

Svoboda M, Sana J, Redova M, Navratil J, Palacova M, Fabian P, Slaby O, Vyzula R.

Diagn Pathol. 2012 Mar 22;7:31. doi: 10.1186/1746-1596-7-31.

16.

High ERK protein expression levels correlate with shorter survival in triple-negative breast cancer patients.

Bartholomeusz C, Gonzalez-Angulo AM, Liu P, Hayashi N, Lluch A, Ferrer-Lozano J, Hortobágyi GN.

Oncologist. 2012;17(6):766-74. doi: 10.1634/theoncologist.2011-0377. Epub 2012 May 14.

17.

Stem cell-like gene expression in ovarian cancer predicts type II subtype and prognosis.

Schwede M, Spentzos D, Bentink S, Hofmann O, Haibe-Kains B, Harrington D, Quackenbush J, Culhane AC.

PLoS One. 2013;8(3):e57799. doi: 10.1371/journal.pone.0057799. Epub 2013 Mar 11.

18.

Genomic subtypes of breast cancer identified by array-comparative genomic hybridization display distinct molecular and clinical characteristics.

Jönsson G, Staaf J, Vallon-Christersson J, Ringnér M, Holm K, Hegardt C, Gunnarsson H, Fagerholm R, Strand C, Agnarsson BA, Kilpivaara O, Luts L, Heikkilä P, Aittomäki K, Blomqvist C, Loman N, Malmström P, Olsson H, Johannsson OT, Arason A, Nevanlinna H, Barkardottir RB, Borg A.

Breast Cancer Res. 2010;12(3):R42. doi: 10.1186/bcr2596. Epub 2010 Jun 24.

19.

Clinicopathological features of triple-negative breast cancer in Taiwanese women.

Yao-Lung K, Dar-Ren C, Tsai-Wang C.

Int J Clin Oncol. 2011 Oct;16(5):500-5. doi: 10.1007/s10147-011-0211-9. Epub 2011 Apr 1.

PMID:
21455625
20.

[Roles of immunohistochemistry in prognostic assessment of basal-like breast cancer].

Liu H, Fan QH, Zhang ZH, Li X, Yu HP, Liu GZ, Meng FQ.

Zhonghua Bing Li Xue Za Zhi. 2009 Jan;38(1):23-8. Chinese.

PMID:
19489221
Items per page

Supplemental Content

Write to the Help Desk